RxDoctor Payments Data

Misty Douthit

Family · Sheridan, ARNPI 1790914927

Payments from drug & device makers

$1,029in general payments, 2019–2025

Across 64 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$165
  • Teva Pharmaceuticals USA, Inc.$126
  • AbbVie$123
  • Exact Sciences$107
  • Novartis$96
  • Bayer$85
  • plus $326 from 14 others

What the payments were for

  • Food & beverage$1,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,029 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$26,987
Medicare patients
172
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$65,554
MounjaroTirzepatide40$44,266
JardianceEmpagliflozin32$25,284
Tresiba Flextouch U-100Insulin Degludec21$15,919
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,970
Fiasp FlextouchInsulin Aspart (Niacinamide)20$12,676
EliquisApixaban21$11,444
XareltoRivaroxaban11$6,162
TradjentaLinagliptin12$5,896
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,974
Gabapentin141$1,803
Omeprazole169$1,516
Albuterol Sulfate HfaAlbuterol Sulfate46$1,415
Diclofenac Sodium68$1,341
Pregabalin28$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$65,55466 claims
Lilly USA, LLCMounjaro$73$44,26640 claims
Boehringer IngelheimJardiance, Tradjenta$32$31,18044 claims
GSKTrelegy Ellipta$165$14,97023 claims
PfizerEliquis$22$11,44421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,103 family providers in Arkansas.

Other family in Sheridan

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →